Recursion reports Q4 net loss of $93M, cash $391.6M; '24 clinical data readouts planned

RECURSION PHARMACEUTICALS, INC.

2023-FY EPS reported -$1.58 revenue$44,575,000

Net loss $93M in Q4 2023 vs $57.5M a year ago; full-year loss $328.1M vs $239.5M.
Cash and equivalents $391.6M at Dec 31, 2023, down from $549.9M a year earlier.
R&D expenses rose to $69.5M in Q4 from $44M; operating cash burn $287.8M for 2023.
Key clinical milestones: REC-994 Phase 2 data Q3 2024; REC-2282 data Q4 2024; REC-3964 Phase 2 start in 2024.
Named Kristen Rushton as Chief Business Operations Officer; in-licenced Bayer fibrosis program (Target Epsilon) entering IND-enabling.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

RECURSION PHARMACEUTICALS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-24-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.